HRP20100062T1 - Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze - Google Patents

Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze Download PDF

Info

Publication number: HRP20100062T1
Authority: HR; Croatia
Prior art keywords: sequence; glu; fusion peptide; histidine; lys
Prior art date: 2005-09-22

Application number

HR20100062T

Other languages

English (en)

Croatian (hr)

Inventor

Geigle Peter

Wallrapp Christine

Thoenes Eric

Original Assignee

Biocompatibles Uk Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2010-02-02

Publication date

2010-03-31

2010-02-02 Application filed by Biocompatibles Uk Limited filed Critical Biocompatibles Uk Limited

2010-03-31 Publication of HRP20100062T1 publication Critical patent/HRP20100062T1/hr

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 43
230000004927 fusion Effects 0.000 title claims abstract 36
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract 11
102400000322 Glucagon-like peptide 1 Human genes 0.000 title claims abstract 7
108091005804 Peptidases Proteins 0.000 title claims abstract 7
101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
102000035195 Peptidases Human genes 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
235000019833 protease Nutrition 0.000 title 1
150000001413 amino acids Chemical group 0.000 claims abstract 9
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract 7
239000004365 Protease Substances 0.000 claims abstract 6
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 6
150000001408 amides Chemical class 0.000 claims abstract 6
229940024606 amino acid Drugs 0.000 claims abstract 6
238000003776 cleavage reaction Methods 0.000 claims abstract 6
230000007017 scission Effects 0.000 claims abstract 6
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract 5
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims abstract 5
108010076504 Protein Sorting Signals Proteins 0.000 claims abstract 4
229960002885 histidine Drugs 0.000 claims abstract 4
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims abstract 4
CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims abstract 3
WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims abstract 3
SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims abstract 3
MPVGZUDRATZEEE-YFKPBYRVSA-N (2s)-2-amino-3-(3-hydroxyimidazol-4-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1O MPVGZUDRATZEEE-YFKPBYRVSA-N 0.000 claims abstract 3
MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims abstract 3
UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 claims abstract 3
FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims abstract 3
WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims abstract 3
IINRZEIPFQHEAP-UHFFFAOYSA-N 1-aminocycloheptane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCCC1 IINRZEIPFQHEAP-UHFFFAOYSA-N 0.000 claims abstract 3
NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims abstract 3
PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims abstract 3
PJSQECUPWDUIBT-UHFFFAOYSA-N 1-azaniumylcyclooctane-1-carboxylate Chemical compound OC(=O)C1(N)CCCCCCC1 PJSQECUPWDUIBT-UHFFFAOYSA-N 0.000 claims abstract 3
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims abstract 3
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims abstract 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 3
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims abstract 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract 3
KBOJOGQFRVVWBH-ZETCQYMHSA-N N-acetyl-L-histidine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CN=CN1 KBOJOGQFRVVWBH-ZETCQYMHSA-N 0.000 claims abstract 3
102000035554 Proglucagon Human genes 0.000 claims abstract 3
108010058003 Proglucagon Proteins 0.000 claims abstract 3
ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims abstract 3
AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims abstract 2
101800001415 Bri23 peptide Proteins 0.000 claims abstract 2
102400000107 C-terminal peptide Human genes 0.000 claims abstract 2
101800000655 C-terminal peptide Proteins 0.000 claims abstract 2
229930195721 D-histidine Natural products 0.000 claims abstract 2
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 2
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract 2
101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 claims abstract 2
HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims abstract 2
230000002424 anti-apoptotic effect Effects 0.000 claims abstract 2
230000004071 biological effect Effects 0.000 claims abstract 2
230000002779 inactivation Effects 0.000 claims abstract 2
230000000508 neurotrophic effect Effects 0.000 claims abstract 2
210000004027 cell Anatomy 0.000 claims 6
108020004707 nucleic acids Proteins 0.000 claims 6
102000039446 nucleic acids Human genes 0.000 claims 6
150000007523 nucleic acids Chemical class 0.000 claims 6
125000000539 amino acid group Chemical group 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
239000003814 drug Substances 0.000 claims 4
238000004519 manufacturing process Methods 0.000 claims 3
238000000034 method Methods 0.000 claims 3
102000004169 proteins and genes Human genes 0.000 claims 3
108090000623 proteins and genes Proteins 0.000 claims 3
201000010099 disease Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 2
229940079593 drug Drugs 0.000 claims 2
208000015122 neurodegenerative disease Diseases 0.000 claims 2
125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 claims 1
102000009027 Albumins Human genes 0.000 claims 1
108010088751 Albumins Proteins 0.000 claims 1
102400000325 Glucagon-like peptide 1(7-36) Human genes 0.000 claims 1
101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 claims 1
102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
206010022489 Insulin Resistance Diseases 0.000 claims 1
241001465754 Metazoa Species 0.000 claims 1
102000004338 Transferrin Human genes 0.000 claims 1
108090000901 Transferrin Proteins 0.000 claims 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
210000004102 animal cell Anatomy 0.000 claims 1
230000006907 apoptotic process Effects 0.000 claims 1
125000000837 carbohydrate group Chemical group 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
210000001671 embryonic stem cell Anatomy 0.000 claims 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
230000002209 hydrophobic effect Effects 0.000 claims 1
150000002632 lipids Chemical class 0.000 claims 1
244000005700 microbiome Species 0.000 claims 1
239000007790 solid phase Substances 0.000 claims 1
230000002194 synthesizing effect Effects 0.000 claims 1
239000012581 transferrin Substances 0.000 claims 1
230000014616 translation Effects 0.000 claims 1
208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07F—COIN-FREED OR LIKE APPARATUS
- G07F11/00—Coin-freed apparatus for dispensing, or the like, discrete articles
- G07F11/02—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines
- G07F11/04—Coin-freed apparatus for dispensing, or the like, discrete articles from non-movable magazines in which magazines the articles are stored one vertically above the other
- G07F11/16—Delivery means
- G07F11/165—Delivery means using xyz-picker or multi-dimensional article picking arrangements

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HR20100062T 2005-09-22 2010-02-02 Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze HRP20100062T1 (hr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05020718A EP1767545B1 (de)	2005-09-22	2005-09-22	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz

Publications (1)

Publication Number	Publication Date
HRP20100062T1 true HRP20100062T1 (hr)	2010-03-31

Family

ID=35700191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100062T HRP20100062T1 (hr)	2005-09-22	2010-02-02	Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze

Country Status (23)

Country	Link
US (2)	US8431533B2 (de)
EP (5)	EP1767545B1 (de)
JP (2)	JP5222729B2 (de)
KR (1)	KR20080064840A (de)
CN (1)	CN101273058A (de)
AT (1)	ATE448247T1 (de)
AU (1)	AU2006299134B2 (de)
BR (1)	BRPI0616107A2 (de)
CA (1)	CA2619053A1 (de)
CY (1)	CY1109778T1 (de)
DE (1)	DE602005017628D1 (de)
DK (1)	DK1767545T3 (de)
EA (1)	EA013796B1 (de)
ES (3)	ES2397289T3 (de)
HR (1)	HRP20100062T1 (de)
IL (1)	IL188904A0 (de)
PL (1)	PL1767545T3 (de)
PT (1)	PT1767545E (de)
RS (1)	RS51319B (de)
SG (1)	SG165414A1 (de)
SI (1)	SI1767545T1 (de)
WO (1)	WO2007039140A1 (de)
ZA (1)	ZA200803488B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
JP2009513627A (ja) *	2005-10-27	2009-04-02	ペプトロンカンパニーリミテッド	生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
WO2009158704A2 (en) *	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
EP2163243A1 (de) *	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
CN101993485B (zh)	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
ES2587574T3 (es) *	2010-02-11	2016-10-25	F. Hoffmann-La Roche Ag	Conjugados proteicos para la pegilación por transamidación mediada por tripsina y métodos
CN103237806A (zh) *	2010-10-01	2013-08-07	株式会社Mmt	具有免疫球蛋白结合能力的肽
CN102766204B (zh) *	2011-05-05	2014-10-15	天津药物研究院	胰高血糖素样肽-1突变体多肽及其制备方法和其应用
CN102363633B (zh) *	2011-11-16	2013-11-20	天津拓飞生物科技有限公司	胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
BR112015011478B1 (pt) *	2012-11-20	2022-10-25	Mederis Diabetes, Llc	Produtos de peptídeo, seus usos e composição farmacêutica
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104707131A (zh) *	2013-12-13	2015-06-17	上海建华精细生物制品有限公司	一种药物组合物及其制备方法和用途
NZ757113A (en)	2014-05-28	2022-08-26	Mederis Diabetes Llc	Improved peptide pharmaceuticals for insulin resistance
JP6731953B2 (ja)	2015-02-11	2020-07-29	ジーエムエーエックスバイオファームエルエルシー．	Ｇｌｐ−１ｒ抗体融合タンパク質の安定な医薬溶液製剤
KR101661332B1 (ko) *	2015-05-28	2016-09-29	(의료)길의료재단	글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CA3009506A1 (en)	2015-12-23	2017-06-29	The Johns Hopkins University	Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
CN107818433B (zh) *	2016-09-14	2022-07-05	菜鸟智能物流控股有限公司	取件方法、物流信息处理方法及装置、系统
WO2018104558A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
DK3551651T3 (da) *	2016-12-09	2024-05-13	Zealand Pharma As	Acylerede glp-1/glp-2-dobbeltagonister
CN108341880B (zh) *	2017-01-23	2023-07-04	天津药物研究院有限公司	含有胰高血糖素样肽-1和胰高血糖素的片段类似物的嵌合多肽及其用途
KR101827245B1 (ko) *	2017-12-26	2018-02-08	(주)제이유타이드	알라린을 주성분으로 하는 요독증 치료제
FI3735295T3 (fi)	2018-01-03	2024-11-20	Mederis Diabetes Llc	Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon
KR101903564B1 (ko) *	2018-01-31	2018-11-13	한국지질자원연구원	제지공정에서 발생되는 부산물의 재활용 방법
SI4122954T1 (sl)	2018-04-05	2024-07-31	Sun Pharmaceutical Industries Limited	Novi analogi GLP-1
CA3123979A1 (en)	2018-12-21	2020-06-25	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
KR102349717B1 (ko) *	2020-03-12	2022-01-11	주식회사 에스엘메타젠	신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
BR112022018134A2 (pt) *	2020-03-12	2022-11-22	Sl Metagen	Proteína biespecífica nova e seu uso
KR20220008788A (ko) *	2020-07-14	2022-01-21	(주)지아이이노베이션	글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
MX2023006188A (es) *	2020-11-27	2023-07-13	D&D Pharmatech Inc	Conjugado de material biologicamente activo que tiene acoplado un resto de biotina, un resto de acido graso o una combinacion de estos.
JP2023551480A (ja) *	2020-11-27	2023-12-08	ディーアンドディーファーマテックインコーポレイテッド	ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤
US12171806B2 (en)	2021-09-28	2024-12-24	Spitfire Pharma Llc	Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
CN112661862B (zh) *	2020-12-25	2023-03-31	深圳大学	一种融合蛋白及其制备方法和应用
CN113846124A (zh) *	2021-09-26	2021-12-28	康霖生物科技（杭州）有限公司	一种用于糖代谢相关疾病基因治疗的核酸构建体
CN115850438B (zh) *	2021-12-28	2023-05-12	北京惠之衡生物科技有限公司	一种长效glp-1衍生物
CN115920004A (zh) *	2022-11-11	2023-04-07	深圳市图微安创科技开发有限公司	药物组合物及其制备方法
JPWO2024135375A1 (de)	2022-12-22	2024-06-27
WO2024144431A1 (ru) *	2022-12-29	2024-07-04	Авва Фармасьютикалс Лтд	Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
WO2025005743A1 (ko) *	2023-06-30	2025-01-02	주식회사 휴온스랩	Glp 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US586128A (en) *		1897-07-13		Toilet-paper holder
US4352883A (en) *	1979-03-28	1982-10-05	Damon Corporation	Encapsulation of biological material
EP0018435B1 (de)	1979-10-16	1984-03-07	Winfried Dr. med. Stöcker	Vorrichtung zur Durchführung von Mikroanalysen
US4596792A (en)	1981-09-04	1986-06-24	The Regents Of The University Of California	Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja)	1982-08-30	1984-03-02	Musashi Eng Kk	紙葉判別方法
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
DD224119A1 (de)	1983-11-07	1985-06-26	Univ Schiller Jena	Temperierbarer probentraeger
US4599231A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US4608251A (en)	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US5116943A (en)	1985-01-18	1992-05-26	Cetus Corporation	Oxidation-resistant muteins of Il-2 and other protein
US4601903A (en)	1985-05-01	1986-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5144139A (en)	1985-08-05	1992-09-01	Biotrack, Inc.	Capillary flow device
US4687529A (en)	1985-08-30	1987-08-18	Miles Laboratories, Inc.	Method of making a reagent test device containing hydrophobic barriers
CA1292176C (en)	1985-09-18	1991-11-19	Joel M. Blatt	Volume metering capillary gap device for applying a liquid sample onto a reactive surface
US5017691A (en)	1986-07-03	1991-05-21	Schering Corporation	Mammalian interleukin-4
US6849708B1 (en)	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
JP3262329B2 (ja)	1990-01-24	2002-03-04	アイ．バックレイ，ダグラス	糖尿病治療に有用なｇｌｐ―１アナログ
ATE138102T1 (de)	1991-02-19	1996-06-15	Takeda Chemical Industries Ltd	Verfahren zur herstellung von cysteinfreien peptiden
CA2062338A1 (en)	1991-03-15	1992-09-16	Zia Yassinzadeh	Electronic control cartridge and method of simulating light transmission patterns
GB9311147D0 (en)	1993-05-28	1993-07-14	Long Ashton Research Station	Regulation of plant growth
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
BE1008987A3 (fr)	1995-01-06	1996-10-01	Robyn Pierre	Blocs refractaires a canalisations pour sols de fours verriers et installation dans les sols de circuits de refroidissement ou de chauffage, permettant d'ameliorer le controle thermique des sols et la qualite du verre.
JP3643863B2 (ja)	1995-08-09	2005-04-27	アークレイ株式会社	液体保持具とその製造方法
UA70283C2 (en)	1996-03-01	2004-10-15	Novo Nordisk As	Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants)
US6165739A (en)	1996-03-13	2000-12-26	Compucyte Corporation	Multiple simultaneous testing media
EP0966297B2 (de) *	1996-08-08	2013-02-27	Amylin Pharmaceuticals, Inc.	Regulation gastrointestinaler beweglichkeit
CZ300837B6 (cs) *	1996-08-30	2009-08-26	Novo Nordisk A/S	Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
ES2290799T3 (es)	1996-11-12	2008-02-16	Novo Nordisk A/S	Uso de peptidos glp-1.
CA2318376A1 (en)	1998-01-12	1999-07-15	Betagene, Inc.	Compositions and methods for regulated secretion from neuroendocrine cell lines
EP1059938A1 (de)	1998-03-06	2000-12-20	Spectrx, Inc.	Photothermische anordnung für biomedizinische anwendungen und verfahren dafür
AU757658B2 (en) *	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6267954B1 (en)	1999-11-24	2001-07-31	Universite De Paris V Rene-Descartes	Intraocular transplantation of encapsulated cells
US6706159B2 (en)	2000-03-02	2004-03-16	Diabetes Diagnostics	Combined lancet and electrochemical analyte-testing apparatus
AU2001237254A1 (en)	2000-03-08	2001-09-17	Novo-Nordisk A/S	Lowering serum lipids
DE10039643A1 (de) *	2000-08-14	2002-02-28	Max Planck Gesellschaft	Funktionalisierte Perylentetracarbonsäurediimide
AU2689702A (en)	2000-12-07	2002-06-18	Lilly Co Eli	Glp-1 fusion proteins
AU2002255517A1 (en)	2001-02-09	2002-10-08	The University Of Illinois	Method and structure for microfluidic flow guiding
US20020183253A1 (en)	2001-02-22	2002-12-05	Brazzell Romulus Kimbro	Method of treating ocular neovascularization
US20030034147A1 (en)	2001-05-31	2003-02-20	Houck Glenn M.	Apparatus which eliminates the need for idling by trucks
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
CN1363654A (zh)	2001-07-19	2002-08-14	上海华谊生物技术有限公司	生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
WO2003010305A1 (en)	2001-07-27	2003-02-06	Arhus Amt	Immortilized stem cells
EP2022505B1 (de)	2001-07-31	2011-12-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
US20040143104A1 (en)	2001-08-08	2004-07-22	Wadsworth Samuel C.	Methods of treating diabetes and other blood sugar disorders
EP1432430A4 (de)	2001-08-28	2006-05-10	Lilly Co Eli	Vormischungen von glp-1 und basalinsulin
US7176278B2 (en) *	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US7166208B2 (en)	2004-03-03	2007-01-23	Stephen Eliot Zweig	Apoenzyme reactivation electrochemical detection method and assay
DE60217918T2 (de)	2001-12-29	2007-11-15	Novo Nordisk A/S	Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
AR038102A1 (es) *	2002-01-08	2004-12-29	Lilly Co Eli	Analogos extendidos de peptido 1 de tipo glucagon
GB2388898B (en)	2002-04-02	2005-10-05	Inverness Medical Ltd	Integrated sample testing meter
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20030143113A2 (en)	2002-05-09	2003-07-31	Lifescan, Inc.	Physiological sample collection devices and methods of using the same
JP2006501820A (ja)	2002-09-06	2006-01-19	バイエル・フアーマシユーチカルズ・コーポレーシヨン	修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
JP4548335B2 (ja)	2003-03-07	2010-09-22	味の素株式会社	腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
US6969166B2 (en)	2003-05-29	2005-11-29	3M Innovative Properties Company	Method for modifying the surface of a substrate
US7057116B2 (en)	2003-06-02	2006-06-06	Intel Corporation	Selective reference plane bridge(s) on folded package
EP1641823B1 (de) *	2003-06-12	2011-09-21	Eli Lilly And Company	Fusionsproteine von glp-1-analoga
EP1498143A1 (de)	2003-07-18	2005-01-19	Aventis Pharma S.A.	Selbstemulgierende und selbstmicroemulgierende Formulierungen zur oralen Verabreichung von Taxoiden
EP1654004A2 (de)	2003-08-08	2006-05-10	Novo Nordisk A/S	Synthese und applikation von neuen strukturellen gut definierten verzweigten polymeren als konjugatmittel für peptide
WO2005035553A2 (en)	2003-10-10	2005-04-21	Novo Nordisk A/S	Conjugation of peptides
CN1893980A (zh) *	2003-12-18	2007-01-10	诺沃挪第克公司	与白蛋白样物质相连的新glp－1类似物
US7670844B2 (en)	2004-01-20	2010-03-02	The Curators Of The University Of Missouri	Supported molecular biofluid viscosity sensors for in vitro and in vivo use
NZ579621A (en)	2004-02-11	2011-03-31	Amylin Pharmaceuticals Inc	Hybrid polypeptides with selectable properties
BRPI0418539A (pt)	2004-03-05	2007-05-22	Egomedical Swiss Ag	sistema de teste de analito para a determinação da concentração de um analito em um fluido fisiológico
JP2008537873A (ja)	2004-03-31	2008-10-02	セントカー・インコーポレーテツド	ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
US20080300173A1 (en) *	2004-07-13	2008-12-04	Defrees Shawn	Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
ATE445020T1 (de)	2004-08-13	2009-10-15	Egomedical Technologies Ag	Analyttestsystem zur bestimmung der konzentration eines analyten in einer physiologischen oder wässrigen flüssigkeit
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
BRPI0615538A2 (pt)	2005-07-29	2011-05-17	Amprotein Corp	proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição farmacêutica, composição alimentar, método para a redução do peso corpóreo, método para o tratamento de diabetes, método para aumentar a vida média de um peptìdio ou uma proteìna terapêutica recombinante em um indivìduo, método para aumentar a eficácia de um peptìdio ou proteìna terapêutica, método para o tratamento de diabetes ou redução do peso corpóreo
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de)	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de)	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2163243A1 (de)	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern

2005
- 2005-09-22 DE DE602005017628T patent/DE602005017628D1/de active Active
- 2005-09-22 PT PT05020718T patent/PT1767545E/pt unknown
- 2005-09-22 EP EP05020718A patent/EP1767545B1/de active Active
- 2005-09-22 ES ES08021837T patent/ES2397289T3/es active Active
- 2005-09-22 SI SI200530887T patent/SI1767545T1/sl unknown
- 2005-09-22 AT AT05020718T patent/ATE448247T1/de active
- 2005-09-22 EP EP08021837A patent/EP2045265B1/de active Active
- 2005-09-22 PL PL05020718T patent/PL1767545T3/pl unknown
- 2005-09-22 DK DK05020718.2T patent/DK1767545T3/da active
- 2005-09-22 RS RSP-2010/0039A patent/RS51319B/sr unknown
- 2005-09-22 ES ES05020718T patent/ES2336575T3/es active Active
2006
- 2006-09-22 WO PCT/EP2006/009226 patent/WO2007039140A1/en active Application Filing
- 2006-09-22 KR KR1020087009543A patent/KR20080064840A/ko not_active Ceased
- 2006-09-22 ZA ZA200803488A patent/ZA200803488B/xx unknown
- 2006-09-22 EP EP10009718A patent/EP2261245A1/de not_active Withdrawn
- 2006-09-22 ES ES06792228T patent/ES2394218T3/es active Active
- 2006-09-22 US US11/991,562 patent/US8431533B2/en not_active Expired - Fee Related
- 2006-09-22 EA EA200800699A patent/EA013796B1/ru not_active IP Right Cessation
- 2006-09-22 CA CA002619053A patent/CA2619053A1/en not_active Abandoned
- 2006-09-22 BR BRPI0616107-3A patent/BRPI0616107A2/pt not_active IP Right Cessation
- 2006-09-22 AU AU2006299134A patent/AU2006299134B2/en not_active Ceased
- 2006-09-22 CN CNA2006800350367A patent/CN101273058A/zh active Pending
- 2006-09-22 SG SG201006921-9A patent/SG165414A1/en unknown
- 2006-09-22 EP EP06792228A patent/EP1926748B1/de not_active Not-in-force
- 2006-09-22 JP JP2008531616A patent/JP5222729B2/ja not_active Expired - Fee Related
- 2006-09-22 EP EP09014513A patent/EP2174952A3/de not_active Withdrawn
2008
- 2008-01-21 IL IL188904A patent/IL188904A0/en unknown
2010
- 2010-02-02 HR HR20100062T patent/HRP20100062T1/hr unknown
- 2010-02-11 CY CY20101100139T patent/CY1109778T1/el unknown
2012
- 2012-05-29 US US13/482,354 patent/US8853159B2/en not_active Expired - Fee Related
2013
- 2013-01-25 JP JP2013012558A patent/JP2013099352A/ja active Pending

Also Published As

Publication number	Publication date
CY1109778T1 (el)	2014-09-10
EA013796B1 (ru)	2010-06-30
EP1767545A1 (de)	2007-03-28
US20110130329A1 (en)	2011-06-02
PL1767545T3 (pl)	2010-04-30
EP2174952A2 (de)	2010-04-14
DK1767545T3 (da)	2010-03-15
EP2045265A1 (de)	2009-04-08
SI1767545T1 (sl)	2010-03-31
US8431533B2 (en)	2013-04-30
DE602005017628D1 (de)	2009-12-24
EA200800699A1 (ru)	2008-10-30
PT1767545E (pt)	2010-02-05
EP2174952A3 (de)	2010-11-17
EP1926748A1 (de)	2008-06-04
JP2009508505A (ja)	2009-03-05
EP2261245A1 (de)	2010-12-15
JP2013099352A (ja)	2013-05-23
EP1767545B1 (de)	2009-11-11
ES2394218T3 (es)	2013-01-23
ATE448247T1 (de)	2009-11-15
US20120238497A1 (en)	2012-09-20
ES2336575T3 (es)	2010-04-14
CA2619053A1 (en)	2007-04-12
JP5222729B2 (ja)	2013-06-26
HK1129121A1 (en)	2009-11-20
BRPI0616107A2 (pt)	2011-06-07
EP2045265B1 (de)	2012-11-21
WO2007039140A1 (en)	2007-04-12
RS51319B (sr)	2010-12-31
US8853159B2 (en)	2014-10-07
AU2006299134B2 (en)	2012-02-23
KR20080064840A (ko)	2008-07-09
AU2006299134A1 (en)	2007-04-12
EP1926748B1 (de)	2012-08-29
SG165414A1 (en)	2010-10-28
ZA200803488B (en)	2009-10-28
ES2397289T3 (es)	2013-03-06
IL188904A0 (en)	2008-04-13
CN101273058A (zh)	2008-09-24

Publication	Publication Date	Title
HRP20100062T1 (hr)	2010-03-31	Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze
CA2550050A1 (en)	2005-06-30	Novel glp-1 analogues linked to albumin-like agents
JP6006309B2 (ja)	2016-10-12	作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP6121330B2 (ja)	2017-04-26	作用持続時間が増した改変ポリペプチド
CA2434237C (en)	2012-05-15	Glp-1 fusion proteins
CA2549582A1 (en)	2005-06-30	Novel glp-1 compounds
Kumar et al.	2007	Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice
Tan et al.	2018	Recent advances in half-life extension strategies for therapeutic peptides and proteins
NO325273B1 (no)	2008-03-17	GLP-1-derivater
US20070161087A1 (en)	2007-07-12	Glp-1 fusion proteins
CN101868476A (zh)	2010-10-20	胰高血糖素样肽-1衍生物及其制药用途
CA2660835A1 (en)	2008-02-21	Dpp-iv resistant gip hybrid polypeptides with selectable propperties
AU2002226897A1 (en)	2002-08-22	GLP-1 fusion proteins
US20170368147A1 (en)	2017-12-28	Chemically and thermodynamically stable insulin analogues and improved methods for their production
WO2022117044A1 (en)	2022-06-09	Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
CN113105561B (zh)	2021-12-03	一种双靶点融合蛋白的制备方法和应用
JP2020519250A5 (de)	2021-06-10
Kühn-Wache et al.	2000	Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance
CN100445300C (zh)	2008-12-24	Glp-1融合蛋白及其制备方法和医药用途
RU2008137376A (ru)	2010-05-20	Полипептидный антагонист
CN101906156B (zh)	2012-10-10	一种双功能蛋白及其衍生物的结构及用途
US9006176B2 (en)	2015-04-14	Chemically and thermodynamically stable insulin analogues and improved methods for their production
Kim et al.	2010	Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic
Zheng et al.	2024	Customizable Click Biochemistry Strategy for the Design and Preparation of Glucagon-like Peptide-1 Conjugates and Coagonists
RU2024106867A (ru)	2024-06-05	Аффимеры, связывающиеся с неонатальным Fc рецептором